UBX4 Antibody

What is UBX4 and what cellular functions does it participate in?

UBX4 is a cofactor protein of Cdc48/p97, containing the ubiquitin regulatory X (UBX) domain which mediates interaction with Cdc48/VCP/p97 complex. UBX4 functions primarily in endoplasmic reticulum-associated protein degradation (ERAD) . Additionally, in conjunction with Cdc48, it plays a critical role in maintaining optimal proteasome levels for anaphase proteolysis during cell division . The Cdc48-Ubx4 complex appears to act on the proteasome and utilizes chaperone activity to promote nuclear distribution of proteasomes, thereby optimizing proteasome levels for efficient degradation of mitotic regulators . UBX4 is one of seven UBX domain proteins (Ubx1-7) identified in budding yeast, with the UBX domain being structurally similar to ubiquitin .

What types of UBX4 antibodies are available and how do they differ in research applications?

Based on antibody research patterns, UBX4 antibodies are typically available as monoclonal, polyclonal, and recombinant types. Research indicates that recombinant antibodies generally demonstrate superior performance compared to monoclonal or polyclonal antibodies when tested against their target proteins . This performance difference is critical when selecting antibodies for detecting proteins like UBX4 that may undergo post-translational modifications. Monoclonal antibodies offer high specificity for a single epitope, while polyclonal antibodies recognize multiple epitopes. For UBX4 detection, the choice between these antibody types depends on experimental goals, particularly considering that UBX4 appears as multiple bands on Western blots due to phosphorylation at various sites .

How can I determine if a commercial UBX4 antibody is detecting the intended target?

Validation of UBX4 antibodies should follow standardized characterization approaches using parental and knockout cell lines to definitively confirm specificity . Researchers should perform side-by-side comparisons of multiple commercial antibodies against UBX4, preferably from different manufacturers. A properly validated UBX4 antibody should show specific signals in wild-type cells that are absent in UBX4 knockout cells . Additionally, for UBX4, researchers should consider the appearance of multiple bands in Western blots due to phosphorylation patterns, as UBX4 is likely phosphorylated at multiple sites including but not limited to S104, S264, S344, T398, and S399 . According to large-scale antibody validation studies, approximately 20-30% of protein studies may utilize ineffective antibodies, highlighting the importance of independent assessment .

What are the optimal conditions for detecting UBX4 phosphorylation using antibodies?

For detecting phosphorylated forms of UBX4, researchers should implement Phos-tag SDS-PAGE followed by Western blotting, as this technique has successfully revealed that UBX4 appears as multiple bands regardless of treatment conditions . Standard SDS-PAGE may not resolve these phosphorylation differences effectively. When designing experiments to detect UBX4 phosphorylation, it's important to note that previously reported phosphorylation sites (S104, S264, S344, T398, and S399) may not account for all phosphorylation events, as site-directed mutagenesis studies have shown . Researchers should consider using phosphatase inhibitors during sample preparation and may need to develop phospho-specific antibodies for particular sites of interest. Lambda phosphatase treatment can serve as a control to confirm that mobility shifts are indeed due to phosphorylation.

How should I optimize Western blot protocols specifically for UBX4 detection?

When optimizing Western blot protocols for UBX4 detection, consider that UBX4 appears as multiple bands on Phos-tag gels . Standard protocol optimization should include:

Additionally, prepare parallel samples with and without phosphatase treatment to distinguish phosphorylation-dependent mobility shifts. For UBX4, which likely has multiple phosphorylation sites beyond those previously documented (S104, S264, S344, T398, and S399), include positive controls with known phosphorylation states when possible .

What are the recommended immunoprecipitation techniques for studying UBX4 interactions with Cdc48/p97?

For investigating UBX4 interactions with Cdc48/p97, co-immunoprecipitation experiments should account for the role of UBX4 as an adaptor protein. The UBX domain mediates interaction with Cdc48/VCP/p97, so antibodies targeting epitopes within this domain may disrupt the interaction . Instead, use antibodies targeting N-terminal or C-terminal regions of UBX4 that don't interfere with the UBX domain. A recommended approach includes:

• Cross-linking prior to cell lysis to stabilize transient interactions

• Using mild detergents (0.5-1% NP-40 or Triton X-100) to preserve protein complexes

• Including ATP in buffers (1-5 mM) as Cdc48-UBX4 interactions may be ATP-dependent

• Performing reciprocal IPs with both UBX4 and Cdc48 antibodies to confirm interactions

• Including controls for non-specific binding

Remember that UBX4 functions alongside Cdc48 in endoplasmic reticulum-associated degradation and proteasome distribution, so experimental conditions should preserve these functional complexes .

How can I address the problem of non-specific binding when using UBX4 antibodies?

Non-specific binding is a common challenge with antibodies, including those targeting UBX4. Large-scale antibody validation studies have shown that many commercial antibodies fail to recognize their intended targets specifically . To minimize non-specific binding with UBX4 antibodies:

• Validate antibody specificity using UBX4 knockout cells as negative controls, which provides the most definitive assessment of specificity

• Test multiple antibodies targeting different epitopes of UBX4 in side-by-side comparisons

• Optimize blocking conditions (consider 5% BSA, 5% milk, or commercial blocking buffers)

• Include competing peptides corresponding to the antibody epitope to confirm specificity

• Use recombinant antibodies when available, as they have demonstrated better performance than monoclonal or polyclonal antibodies in large-scale studies

• Adjust antibody concentration through careful titration experiments

If persistent non-specific binding occurs, consider alternative detection methods such as epitope tagging of UBX4 in model systems where genetic manipulation is possible.

Why might UBX4 antibodies show inconsistent results across different cell types or experimental conditions?

Inconsistent results with UBX4 antibodies across different cell types or conditions may stem from several factors:

• Post-translational modifications: UBX4 undergoes multiple phosphorylation events at sites beyond those previously documented (S104, S264, S344, T398, and S399) . Different cell types or conditions may alter these modification patterns, affecting antibody recognition.

• Protein complex formation: As an adaptor protein for Cdc48/p97, UBX4 exists in different protein complexes that might mask epitopes in cell-type specific ways .

• Antibody quality variation: Batch-to-batch variation in commercial antibodies remains a significant issue, with studies showing that hundreds of underperforming antibodies continue to be used in published research .

• Expression levels: UBX4 expression may vary across cell types, requiring adjustment of detection protocols.

• Extraction methods: UBX4's association with the proteasome and nuclear structures may require specific extraction protocols to maintain its native state and antibody accessibility .

To address these inconsistencies, standardize experimental protocols, validate antibodies in each cell type being studied, and consider using multiple antibodies targeting different epitopes to confirm results.

What strategies can resolve difficulties in detecting phosphorylated forms of UBX4?

Detecting phosphorylated forms of UBX4 presents specific challenges since it appears as multiple bands on Phos-tag gels and likely contains multiple phosphorylation sites beyond those previously reported . To improve detection of phosphorylated UBX4:

• Use Phos-tag SDS-PAGE: This specialized technique has successfully resolved multiple phosphorylated forms of UBX4 .

• Combine with phosphatase inhibitors: Include phosphatase inhibitors in lysis buffers to preserve phosphorylation states.

• Perform parallel phosphatase treatment: Include samples treated with lambda phosphatase as controls to confirm phosphorylation-dependent mobility shifts.

• Consider developing phospho-specific antibodies: For specific research questions about particular phosphorylation sites.

• Mass spectrometry analysis: To identify and map all phosphorylation sites on UBX4 before designing targeted detection strategies.

• Two-dimensional gel electrophoresis: Can provide better resolution of differently phosphorylated forms than one-dimensional approaches.

Since site-directed mutagenesis of previously reported phosphorylation sites (S104, S264, S344, T398, and S399) did not eliminate the multiple band pattern, researchers should be prepared to identify and characterize additional phosphorylation sites on UBX4 .

How can UBX4 antibodies be utilized to study proteasome distribution and function?

UBX4 antibodies can be powerful tools for investigating proteasome distribution and function, given the role of Cdc48-Ubx4 in maintaining optimal proteasome levels and distribution . Advanced research applications include:

• Immunofluorescence microscopy: Using validated UBX4 antibodies alongside proteasome markers to track proteasome distribution. This is particularly valuable because mutations in Cdc48 and Ubx4 cause mislocalization of the 26S proteasome into foci that colocalize with nuclear envelope anchor Sts1 .

• Chromatin immunoprecipitation (ChIP): For studying potential nuclear roles of UBX4 in proteasome regulation during cell cycle progression.

• Proximity labeling approaches: Combining UBX4 antibodies with BioID or APEX2 approaches to identify proteins in proximity to UBX4 during different cellular states.

• Live cell imaging: Using fluorescently tagged UBX4 alongside proteasome markers to track dynamic changes in distribution during cell cycle progression.

• Fractionation studies: Using UBX4 antibodies to track proteasome association with different cellular compartments.

These approaches can help elucidate how Cdc48-Ubx4 uses chaperone activity to promote nuclear distribution of proteasomes, thereby optimizing proteasome levels for efficient degradation of mitotic regulators .

What are the considerations for using UBX4 antibodies in studying cell cycle regulation and mitotic progression?

When using UBX4 antibodies to study cell cycle regulation and mitotic progression, researchers should consider:

• Cell synchronization: Synchronize cells at different cell cycle stages to capture dynamic changes in UBX4 phosphorylation and localization.

• Multiple detection methods: Combine immunofluorescence, Western blotting, and co-immunoprecipitation to build a comprehensive picture of UBX4 function.

• Key interacting partners: Design experiments to detect interactions between UBX4, Cdc48, and proteasome components that are critical for anaphase proteolysis .

• Relationship to mitotic substrates: Include detection of mitotic regulators like Clb2 and Cdc20, which are sustained in double mutations of Cdc48 and Ubx4 .

• Genetic backgrounds: Consider using strains with mutations in other proteasome regulators like Rpn4 (a transcriptional activator for proteasome subunits) to understand genetic interactions .

The relationship between UBX4 and cell cycle regulation is significant because double mutations in Cdc48 and Ubx4 cause mitotic arrest with sustained levels of proteins that should be degraded during anaphase . This makes UBX4 antibodies valuable tools for dissecting mechanisms of proteasome-mediated protein degradation during mitosis.

How can multiplexed antibody approaches be designed to study UBX4 in protein quality control pathways?

Designing multiplexed antibody approaches to study UBX4 in protein quality control pathways requires careful consideration of UBX4's roles in both endoplasmic reticulum-associated degradation (ERAD) and proteasome distribution . Advanced multiplexed strategies include:

When designing these approaches, researchers should account for potential epitope masking in protein complexes and consider the phosphorylation state of UBX4, which appears as multiple bands by Phos-tag analysis . Additionally, including antibodies against ERAD substrates can provide functional readouts of the UBX4-dependent degradation pathway. Given that UBX4 functions alongside Ubx2 in ERAD , comparative analysis of multiple UBX domain proteins can provide insights into their specialized functions.

How should multiple band patterns of UBX4 in Western blots be interpreted?

The interpretation of multiple UBX4 bands in Western blots requires careful analysis as UBX4 appears as multiple bands by Phos-tag, regardless of treatment conditions . When analyzing these patterns:

• Phosphorylation status: Multiple bands likely represent different phosphorylation states. Site-directed mutagenesis has shown that previously reported phosphorylation sites (S104, S264, S344, T398, and S399) do not fully account for these patterns, suggesting additional phosphorylation sites exist .

• Band shifts during cell cycle: Compare band patterns across synchronized cell populations to identify cell cycle-specific phosphorylation events, particularly given UBX4's role in mitotic progression .

• Comparison with other UBX proteins: Unlike UBX4, proteins like Ubx2, Ubx3, Ufd1, Npl4, and Doa1 appear as single predominant bands in both normal and Phos-tag Western blotting . This suggests unique regulation of UBX4.

• Treatment responses: While UBX4 bands appear regardless of treatment, proteins like Ubx5, Ubx6, and Ubx7 show subtle changes upon rapamycin treatment . These comparative patterns provide context for UBX4 regulation.

• Antibody specificity confirmation: Validate that all bands are indeed UBX4 using knockout controls, as commercial antibodies often detect unintended targets .

The multiple band pattern of UBX4 should be interpreted as evidence of its complex post-translational regulation, potentially related to its diverse functions in ERAD and proteasome distribution .

What controls are essential when publishing research using UBX4 antibodies?

When publishing research using UBX4 antibodies, include these essential controls to ensure validity and reproducibility:

• Knockout/knockdown validation: Demonstrate antibody specificity using UBX4 knockout or knockdown samples. This is the gold standard for antibody validation .

• Multiple antibody verification: Confirm key findings using at least two different antibodies targeting distinct epitopes of UBX4.

• Recombinant protein controls: Include purified recombinant UBX4 as a positive control for antibody specificity, as recombinant antibodies have shown better performance in large-scale studies .

• Phosphorylation controls: For phosphorylation studies, include phosphatase-treated samples to confirm that band shifts are phosphorylation-dependent .

• Cross-reactivity assessment: Test antibody reactivity against other UBX family proteins (Ubx1-7) to rule out cross-reactivity, particularly important since these proteins share the UBX domain .

• Antibody validation metadata: Report complete antibody information including manufacturer, catalog number, lot number, dilution, and validation method. This is critical as hundreds of underperforming antibodies remain in use in published literature .

• Genetic complementation: For functional studies, demonstrate rescue of UBX4 knockout/knockdown phenotypes with wild-type UBX4 expression.

These controls are essential because approximately 20-30% of protein studies use ineffective antibodies, indicating a substantial need for independent assessment of commercial antibodies .

How can researchers distinguish between UBX4's multiple functional roles when interpreting antibody-based experiments?

Distinguishing between UBX4's roles in ERAD, proteasome distribution, and cell cycle regulation requires thoughtful experimental design and interpretation:

• Cellular compartment analysis: Use subcellular fractionation followed by Western blotting with UBX4 antibodies to track distribution between ER, cytosol, and nucleus. UBX4's role in ERAD would manifest primarily at the ER, while its proteasome distribution function involves nuclear localization .

• Interactome analysis: Compare UBX4 co-immunoprecipitation results under conditions that favor either ERAD (ER stress) or cell cycle regulation (synchronized cells). Different interacting partners will indicate which functional complex is being studied.

• Functional readouts: Measure distinct endpoints for each pathway:

  • ERAD function: Degradation rates of known ERAD substrates

  • Proteasome distribution: Localization of proteasome subunits

  • Cell cycle regulation: Levels of anaphase substrates like Clb2 and Cdc20

• Genetic background effects: Compare UBX4 antibody results in different genetic backgrounds, such as cells lacking Rpn4 (proteasome transcription factor) versus ERAD components .

• Phosphorylation state correlation: Connect specific UBX4 phosphorylation patterns (multiple bands on Phos-tag gels) with particular functions through temporal analysis during cell cycle progression or stress responses .

When interpreting results, consider that double mutations in Cdc48 and Ubx4 cause the 26S proteasome to mislocalize into foci that colocalize with nuclear envelope anchor Sts1, suggesting a primary role in proteasome distribution that affects downstream processes including mitotic progression .

What emerging techniques might improve UBX4 antibody specificity and research applications?

Emerging techniques with potential to enhance UBX4 antibody research include:

• Single-domain antibodies (nanobodies): Smaller antibody fragments derived from camelid antibodies may provide better access to epitopes in complex structures involving UBX4, Cdc48, and the proteasome .

• Recombinant antibody engineering: Custom-designed recombinant antibodies targeting specific UBX4 epitopes, which have demonstrated superior performance in large-scale validation studies .

• Proximity-dependent biotinylation (BioID/TurboID): Fusing biotin ligase to UBX4 to identify proximal proteins in living cells, providing dynamic interactome data without relying solely on antibody specificity.

• CRISPR epitope tagging: Endogenous tagging of UBX4 to enable detection with highly specific commercial tag antibodies, circumventing potential UBX4 antibody limitations.

• Intrabodies: Antibody fragments expressed within cells that can track and potentially modulate UBX4 function in real-time.

• DNA-conjugated antibodies for spatial transcriptomics: Combining UBX4 protein detection with transcriptomic analysis to correlate protein localization with gene expression patterns.

• Machine learning for antibody validation: Computational approaches to predict antibody specificity and cross-reactivity before experimental testing, potentially saving resources on validation.

These techniques could address the current challenges where many commercial antibodies do not recognize their intended targets, a problem that remains largely anecdotal despite its significance .

How might phospho-specific UBX4 antibodies contribute to understanding cell cycle regulation?

Phospho-specific antibodies targeting UBX4 phosphorylation sites could provide transformative insights into cell cycle regulation:

• Cell cycle-specific phosphorylation events: UBX4 appears as multiple bands on Phos-tag gels, indicating multiple phosphorylation sites beyond those previously reported (S104, S264, S344, T398, and S399) . Phospho-specific antibodies could track which sites are modified during specific cell cycle phases.

• Kinase-substrate relationships: Identifying which kinases phosphorylate UBX4 at different sites would establish regulatory connections between cell cycle kinases and UBX4 function.

• Functional consequences: Correlating specific phosphorylation states with UBX4's ability to maintain proteasome distribution for anaphase proteolysis .

• Temporal regulation: Real-time tracking of UBX4 phosphorylation changes during mitotic progression using live-cell imaging with phospho-specific antibodies.

• Molecular mechanisms: Understanding how phosphorylation affects UBX4's interaction with Cdc48 and the proteasome, potentially revealing regulatory switches that control proteasome distribution.

This approach is particularly valuable since double mutations in Cdc48 and Ubx4 cause mitotic arrest with sustained levels of proteins like Clb2 and Cdc20 that should be degraded during anaphase . Phospho-specific antibodies could reveal exactly how UBX4 regulation connects to this critical cell cycle transition.

What standardized validation approaches should be developed specifically for UBX4 antibodies?

Standardized validation approaches for UBX4 antibodies should incorporate:

• UBX4 knockout cell panel: Develop a panel of cell lines from different species and tissues with UBX4 knockouts to serve as definitive negative controls for antibody validation .

• Phosphorylation state controls: Given UBX4's multiple phosphorylation states , create recombinant UBX4 proteins with defined phosphorylation patterns as standards for antibody testing.

• Cross-reactivity matrix: Systematically test cross-reactivity against all seven UBX family proteins (Ubx1-7) which share the UBX domain .

• Application-specific validation: Define separate validation criteria for different applications (Western blot, immunoprecipitation, immunofluorescence, flow cytometry).

• Epitope mapping: Characterize the precise epitopes recognized by each antibody to better understand potential masking in protein complexes.

• Reproducibility assessment: Implement multi-laboratory testing of the same antibody lots to ensure consistent performance across research environments.

• Database integration: Contribute validation data to public repositories similar to the approach used by Ayoubi et al., who shared antibody validation data on publicly available databases .